Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Slides:

Advertisements

Similar presentations

To enhance students ability to interpret data in charts and graphs To discuss basic concepts in epidemiology and science.

Advertisements

From: An open day in the metric space

Fig. 1 Flow chart of the COBRA-light trial and its extension study

Figure 1 The spatial and temporal distribution of diarrhoea rates

From: Global Banking: Recent Developments and Insights from Research*

Figure 2. Quality of life (QOL) scores for functional scale items

Fig. 1 Graphical representation

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.

Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.

Figure 2. CONSORT flow diagram.

Fig 1 Trends in organ donors in the UK, 2000–10

From: Political Leadership and Power Redistribution

Table 5 Village Characteristics Based on the Census of India 1991, by Mandate during which a First SHG was Created in the Village From: Public Good Provision.

Error bars represent the mean (s.e.).

pSS: primary SS; Scl: scleroderma.

Figure 3. Examples of tweets classified as ridicule.

Figure 1. Logos appearing in the choice experiment

Figure 1. Selection of papers.

Fig. 1 Flow chart of study selection

Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.

Figure 1. VoC conceptual framework linking employment mobility and welfare production regimes From: Complexity in Employment Life Courses in Europe in.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Fig. 1 Flow of ascertainment of cases with incident childhood IgA vasculitis reported by four sources From: Incidence of IgA vasculitis in children estimated.

Fig. 1. Geographic locations of Shenzhen and Dongguan

From: Unmasking Masks in Makkah: Preventing Influenza at Hajj

Figure 1 (A) Chest computed tomography scans of the patient

Fig. 1 Proportion of study participants with ideal Cardiovascular Health Metrics by self-rated health. Ideal category of Cardiovascular Health Metrics.

Figure 2. (A) Sézary syndrome patient before treatment

Figure 2. Kaplan–Meier survival analysis in patients

Fig 1 Respiratory support escalation strategies for study patients

Fig 1 Perfusion index values at different time intervals in patients with successful and failed blocks. A reference line at PI 3.3 is provided. Horizontal.

From: Where do we go from here

Figure 1. Overall survival of patients receiving alternative medicine (solid lines) vs conventional cancer treatment (dashed lines). Overall survival of.

Example 14. Schubert, Quartet in G Major, D

Figure 2. A consort diagram showing the flowchart of the trial

Figure 1. Single-Tree Model and BART Fits to Simulated Data.

Fig. 1 Selection of patients

Figure 1 Study flowchart.

Fig. 1 Flow diagram of patient selection and study design.

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Figure 1 Flow of data processing

From: Estimating the Location of World Wheat Price Discovery

Figure 3. Hypothalamic–Pituitary–Adrenal (HPA)-axis functioning moderates crime exposure: regions of significance on X (crime). The lines represent two.

Figure 1. Time of initiation of therapeutic hypothermia according to who initiated it. Note the logarithmic scaling of the vertical axis. From: Initiation.

Figure 1: Time points at which sperm samples were analysed for aneuploidy frequencies in controls and cancer patients From: Sperm aneuploidy frequencies.

Fig. 2. Comparison of ROC curves for the FR and TR of both versions of the FCSRT for discriminating mild AD patients from cognitively healthy controls.

Figure 3. Visualisation of ESMO-MCB scores for curative and non-curative setting. A & B and 5 and 4 represent the grades with substantial improvement.

Figure 1. Dosage and administration route of drugs used in the BMD study. Each cycle was proposed every 28 days (‘base’ schedule) or 35 days (‘weekly’

Figure 1. Percentage of trainees is represented on the y-axis for each competency/knowledge item represented in the x-axis. Only Poor/Fair (P/F) ratings.

Figure 1. Impact ratings for prospective memory lapses for younger (~age 30), middle-age (~age 50), and older (~age 65) adults. From: Daily Memory Lapses.

Figure 6. RRs for clinical cure rates stratified by different diseases

Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large.

Figure 1. Percentage of participants in each group (holocaust survivors, prewar immigrants, and postwar immigrants) by the main coded strategies. From:

Figure 5. Tungiasis: a 21-year-old woman returned from Peru with painful nodules on her toes. From: Illness in Travelers Returned From Brazil: The GeoSentinel.

Figure 3. Changes from baseline in activated CD4+ T cells (% CD4+CD25+) during the 52-week intervention period in the.

Figure 1. Patterns of HER2–PET/CT confronted with FDG–PET/CT, Maximum intensity projection. Lesion uptake was considered pertinent when visually higher.

Figure 1. Non-biochemical recurrence rate for the entire population (n = 122). From: Salvage radiation therapy for prostate cancer patients after prostatectomy.

Fig. 1 Flow chart of included patients for analyses

Fig. 1 Flow chart for selection of study subjects

Figure 1. Survival curves from a hypothesized clinical trial randomizing patient to standard of care with and without ... Figure 1. Survival curves from.

Figure 1. CONSORT flow diagram

Figure 1 Cumulative late adjusted survival in cardiac resynchronization therapy defibrillator and pacemaker patients. ... Figure 1 Cumulative late adjusted.

Fig. 1 Kaplan-Meier plot presenting no difference in progression to RA in patients with clinically suspect ... Fig. 1 Kaplan-Meier plot presenting no difference.

Figure 1. Oncoprint of selected pathogenic alterations detected in ctDNA. Unless provided in the caption above, the following copyright applies to the.

Figure 2. Biomarkers for prediction of differences in PFS and objective response rate between GP and GT arm in patients ... Figure 2. Biomarkers for prediction.

Figure 2. Forest plot of multivariable Cox proportional hazard regression illustrating the impact of chemoradiation ... Figure 2. Forest plot of multivariable.

Figure 1: Trade shares of South Korea's major trading partners (% of South Korea's total trade in goods) Figure 1: Trade shares of South Korea's major.

Figure 1. Forest plot of lung cancer mortality in LDCT trials.

Presentation transcript:

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal irradiation (CSI) (n = 301). (C) Patients with M0 disease who received 36 Gy CSI (n= 254). Radiation therapy (RT) cohort included patients receiving adjuvant CSI without chemotherapy; chemotherapy and radiotherapy (CRT) cohort included patients receiving CSI and chemotherapy. Analysis includes only patients receiving CSI between 23 and 36 Gy. From: Adjuvant chemotherapy and overall survival in adult medulloblastoma Neuro Oncol. 2016;19(2):259-269. doi:10.1093/neuonc/now150 Neuro Oncol | © The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 1